Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension

Chest

Volumn 110, Issue 3, 1996, Pages 710-717

  Welsh, Carolyn H ^a,b   Hassell, Kathryn L ^b   Badesch, David B ^b   Kressin, David C ^a   Marlar, Richard A ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

coagulation; fibrinolytic activity; pulmonary hypertension; thrombomodulin

Indexed keywords

BLOOD CLOTTING FACTOR; FIBRINOGEN; PLASMINOGEN ACTIVATOR; PROTEIN C; PROTEIN S; THROMBOMODULIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD LEVEL; CONTROLLED STUDY; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

EID: 0030447832     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.110.3.710     Document Type: Article

References (32)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115:343-49
2. Weitzenblum E, Hirth C, Ducolone A, et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981; 36:752-58
3. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and importance of thrombosis. Circulation 1984; 70:580-87
4. Rich S, Kaufmann E, Levy PS. The effect of the high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81
5. Frank K, Gurtner HP, Kneussl M, et al Aminorex-induzierte, plexogene pulmonale arteriopathis: 25 jahre danach! Z.Kardiol 1993; 82:568-72
6. Pietra GG. The histopathology of primary pulmonary hypertension. In: Fishman AP, ed. The pulmonary circulation, normal and abnormal. Philadelphia: University of Pennsylvania Press, 1990; 459-72
7. Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42:1163-84
8. Loyd JE, Atkinson JB, Pietra GG, et al. Heterogeneity of pathologic lesions in familial primary pulmonary hypertension. Am Rev Respir Dis 1988; 138:952-57
9. Wagenvoort CA, Mulder GH. Thrombotic lesions in primary plexogenic arteriopathy. Chest 1993; 103:844-49
10. Reeves JT, Groves BM. Approach to the patient with pulmonary hypertension. In: Weir EK, Reeves JT, eds. Pulmonary hypertension. Mount Kisco, NY: Futura Publishing, 1984; 1-5
11. Dittman WA, Majerus PW. Structure and function of thrombomodulin: a natural anticoagulant. Blood 1990; 75:329-36
12. Madden RM, Gill J, Marlar RA. Protein C and protein S levels in two patients with acquired purpura fulminans. Br J Haematol 1990; 75:112-17
13. Madden RM, Levin EG, Marlar RA. Thrombin and the thrombin-thrombomodulin complex interaction with plasminogen activator inhibitor, type 1. Blood Coagul Fibrinolysis 1991; 2:471-76
14. Gruber A, Griffin J. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79:2340-48
15. Dahlback B, Carlsson N, Svensson P. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90:1004-08
16. Ledford M, Kent J, Civantos F. A comparative study of three methods for the visualization of von Willebrand's factor multimers. Thromb Haemost 1990; 64:569-75
17. Zimmerman TS, Ruggeri ZM. von Willebrand's disease. Prog Hemost Thromb 1982; 6:203-36
18. Steel RG, Torie JH. Principles and procedures of statistics. New York: McGraw-Hill, 1960; 110-11
19. Takano S, Kimura S, Ohdama S, et al. Plasma thrombomodulin in health and diseases. Blood 1990; 76:2024-29
20. Ohdama S, Matsubara O, Aoki N. Plasma thrombomodulin in Wegener's granulomatosis as an indicator of vascular injuries. Chest 1994; 106:666-71
21. Svesson PJ, Dahlback B. Resistance to activated protein C as a basis for venons thrombosis. N Engl J Med 1994; 330:517-22
22. Franz RC, Ziady F, Coetzee WJC, et al. A possible causal relationship between defective fibrinolysis and pulmonary hypertension. S Afr Med J 1979; 55:170-73
23. Inglesby TV, Singer JW, Gordon DS. Abnormal fibrinolysis in familial pulmonary hypertension. Am J Med 1973; 55:5-14
24. Olman MA, Marsh JJ, Lang IM, et al. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension. Circulation 1992; 86:1241-48
25. Geggel RL, Carvallio ACA, Hoyer LW, et al. von Willebrand factor abnormalities in primary pulmonary hypertension. Am Rev Respir Dis 1987; 135:294-99
26. Rabinovitch M, Andrew M, Thom H, et al. Abnormal eudothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation 1987; 76:1043-52
27. Lopes AB, Maeda NY, Aiello VD, et al. Abnormal multimeric and oligomerie composition is associated with enhanced endothelial expression of von Willebrand factor in pulmonary hypertension. Chest 1993; 104:1455-60
28. Alevriadon BR, Moake JL, Turner NA, et al. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1993; 81:1263-76
29. Rubin DB, Wiener-Kronish JP, Murray JF, et al. Elevated on Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 1990; 86:474-80
30. Eisenberg PR, Lucore C, Kaufman L, et al. Fibrinopeptide A levels indicative of pulmonary vascular thrombosisn in patients with primary pulmonary hypertension. Circulation 1990; 82:841-47
31. Schwartz CJ, Valente AJ, Sprague EA, et al. Pathogenesis of the atherosclerotic lesion: implcations for diabetes mellitus. Diabetes Care 1992; 15:1156-67
32. Thompson SG, Kienast J, Pyke SDM, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332:635-41